Novo Nordisk rose 4.8% in early Tuesday trading. The company announced yesterday the launch of Wegovy in the US, starting at $149 per month in cash, and expanding distribution channels through large pharmacies and telemedicine, while Eli Lilly is preparing to launch competitive oral medications.

Novo Nordisk rose 4.8% in early Tuesday trading. The company announced yesterday the launch of Wegovy in the US, starting at $149 per month in cash, and expanding distribution channels through large pharmacies and telemedicine, while Eli Lilly is preparing to launch competitive oral medications.